CSIMarket
 
Eqrx Inc   (EQRX)
Other Ticker:  
 
 
Price: $2.3400 $-0.05 -2.092%
Day's High: $2.42 Week Perf: 0.00
Day's Low: $ 2.32 30 Day Perf: 4.93 %
Volume (M): 16,459 52 Wk High: $ 2.63
Volume (M$): $ 38,515 52 Wk Avg: $2.01
Open: $2.39 52 Wk Low: $1.58



 Market Capitalization (Millions $) 1,133
 Shares Outstanding (Millions) 484
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -260
 Cash Flow (TTM) (Millions $) -682
 Capital Exp. (TTM) (Millions $) 2

Eqrx Inc
Eqrx Inc is a biotech company that specializes in developing and commercializing innovative therapies aimed at improving quality of life for patients globally, primarily focused on oncology, immunology, and neuroscience. The company was founded in 2020 by Alexis Borisy, who is also the CEO, with the aim of creating a new model for drug development and commercialization that is more efficient and affordable compared to traditional pharmaceutical companies.

The company's unique business model combines a technology-based approach with a patient-centric focus to identify and develop therapies that provide the most significant benefit to patients. The company has built an extensive network of industry experts, entrepreneurs, and investors to ensure that it remains at the forefront of innovation in the biotech industry.

Eqrx has a pipeline of promising drug candidates, including EGFR inhibitor, BTK inhibitor, and CD19 CAR-T cell therapies. The company is also developing small molecules for the treatment of autoimmune diseases and has several other preclinical programs underway.

The company's decentralized model of drug development involves a team-based approach with distributed centers of excellence that allows for a rapid and cost-effective development of therapeutic products. This approach eliminates the high overhead costs of traditional pharmaceutical companies, making drug products developed by Eqrx more affordable for patients.

Eqrx has established partnerships with other leading biotech companies and academia to leverage the best available technology and expertise. The company has also attracted top talent from the biotech industry, including scientists, physicians, and drug developers, to work on its innovative projects.

In summary, Eqrx is a rapidly growing biotech company with a unique approach to drug development aimed at creating innovative, affordable, and impactful therapies to enhance the quality of life for patients. The company's decentralized model, cutting-edge technology, and patient-centric focus have set it apart from traditional pharmaceutical companies, making Eqrx a leading force in the biotech industry.


   Company Address: 50 Hampshire Street Cambridge 2139 MA
   Company Phone Number: 315-2255   Stock Exchange / Ticker: NASDAQ EQRX
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Eqrx Inc

Eqrx Inc Witnesses Soaring Expenses During the Thriving July-September 2023 Fiscal Period



EQRX Inc, a prominent company in the industry, recently announced its financial results for the July to September 30, 2023 reporting cycle. While shareholders were caught off guard by some revenue changes, close attention has been paid to the company's operating shortfall during the same period. This article aims to interpret these financial results and set them into context, shedding light on the organization's current situation and potential for future success.
Assessment of the Fiscal Time-frame Result:
During the third quarter of 2022, EQRX Inc experienced an operating shortfall of $-90.366 million. However, during the same period for 2023, the operating shortfall increased to $-101.548 million, indicating a challenging quarter for the company. Despite this setback, there is a silver lining as the losses have receded to $-82.631 million from $-85.092 million in the third quarter of 2022. This reduction in losses may indicate a positive trajectory for EQRX Inc and its potential to establish itself as a leader in the industry.

Eqrx Inc

Eqrx Inc Takes Strides in Reducing Losses, Showing Promising Growth in Recent Fiscal Period

The Major Pharmaceutical Preparations industry veterans are closely analyzing the second quarter financial results of Eqrx Inc, a prominent player in the market. The company has reported an operating loss of $-91.836 million for the period of April to June 30, 2023. It is important to note that Eqrx Inc has not mentioned any revenue figures yet, making it difficult to fully evaluate the financial performance of the company during this quarter.
To put things into perspective, let's compare these numbers with the operating loss from the same quarter last year, which amounted to $-79.09 million. Despite still formulating its business strategy, Eqrx Inc managed to reduce its diminishing Returns in the most recent fiscal period to $-72.956 million, compared to $-82.546 million in the second quarter of 2022. This indicates that the company is making efforts to improve its financial position and cut losses.

Eqrx Inc

Eqrx Inc: Revolutionizing the Pharmaceutical Industry but Facing Financial Hurdles in Q1 2023

Eqrx Inc: A Closer Look at the Operating Shortfall in Q1 2023
Eqrx Inc is a pharmaceutical preparations company that has been in operation since 2018. The company is based in Cambridge, Massachusetts, and has a focus on disrupting the traditional pharmaceutical industry through innovative business models and technology. Eqrx Inc has been making waves in the industry, with notable investments and partnerships from big players like Alphabet and Softbank.
Despite the company's positive reputation in the industry, Eqrx Inc has reported an operating shortfall of $-101.798 million for the first quarter of 2023. This news has raised concerns about the company's financial stability and future prospects.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com